<DOC>
	<DOCNO>NCT00538876</DOCNO>
	<brief_summary>This open label phase I study design explore feasibility , safety biologic activity epigenetic priming decitabine prior standard cytarabine , daunorubicin induction chemotherapy young patient less-than-favorable risk AML . Primary Objective : To find appropriate dose level decitabine use prim cytarabine daunorubicin `` 7+3 '' induction chemotherapy AML . Secondary Objectives : 1 . To establish safety expect toxicity decitabine use prim cytarabine daunorubicin `` 7+3 '' induction chemotherapy AML . 2 . To establish optimal dose schedule decitabine require broadly demethylate cytosine residue genomic regulatory region . 3 . To investigate , select case , molecular cellular consequence decitabine-induced hypomethylation ) establish extent degree hypomethylation specific genomic locus require reactivate expression repress gene b ) determine effect hypomethylation differentiation and/or apoptosis leukemic blast .</brief_summary>
	<brief_title>Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients must histologically cytologically confirm diagnosis Acute Myelogenous Leukemia ( AML ) Patient &gt; 18 ≤ 60 year age . AML subgroup associate lessthanfavorable risk define : The absence good risk molecular feature : ( 8 ; 21 ) , inv ( 16 ) , ( 16 ; 16 ) , ( 15 ; 17 ) translocation identify FISH standard metaphase karyotyping evidence correspond fusion transcript , AML1ETO , CBFβSMMHC , PMLRARα , identify RTPCR suggest FAB M3 phenotype ; A history antecedent myelodysplastic syndrome ; A history antecedent Philadelphiachromosome negative myeloproliferative disorder ( e.g. , polycythemia vera , essential thrombocythemia , primary myelofibrosis ) ; Treatmentrelated AML believe secondary prior cytotoxic chemotherapy unrelated disease . Patient adequate cardiac function define : An echocardiogram MUGA scan demonstrate ejection fraction within normal limit . ECOG performance status &gt; = 2 . Patient adequate hepatic/renal function define : Total bilirubin ≤ 2 mg/dL . Patients document evidence Gilbert 's Syndrome resulting elevate total bilirubin level eligible , provide eligibility criterion meet . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤1.5 x ULN . Creatinine ≤ 2 mg/dL ( creatinine clearance &gt; 50 mL/min/1.73 m2 , direct measure ) . Patient childbearing : Female subject must surgically sterile , postmenopausal , βHCG indicate pregnant time screen perform . Female patient childbearing potential must agree take appropriate measure ensure become pregnant enrolled protocol ( i.e. , within 2 month administration chemotherapy ) . Male patient must agree take appropriate measure ensure father child enrol protocol ( i.e. , within 2 month follow administration chemotherapy ) . Ability understand willingness sign write informed consent document . AML `` good risk '' molecular feature : karyotype demonstrate presence ( 8 ; 21 ) , inv ( 16 ) , ( 16 ; 16 ) , ( 15 ; 17 ) translocation identify FISH standard metaphase karyotyping evidence correspond fusion transcript , AML1ETO , CBFβSMMHC , PMLRARα , identify RTPCR suggest FAB M3 phenotype . Patient history chronic myelogenous leukemia molecular evidence ( 9 ; 22 ) translocation FISH , metaphase karyotype RTPCR BCRABL fusion transcript . Patient receive chemotherapy ( hydroxyurea ) radiation within 2 week prior plan therapy study . Patient active second malignancy . Patient medical condition illness consider Investigator constitute unwarranted high risk investigational drug treatment . Patient uncontrolled serious infection . Patient pregnant nursing infant . Patient psychiatric disorder alter mental status would preclude understand informed consent process and/or completion necessary study . Patient inability unwillingness , opinion Investigator , comply protocol requirement . Patients central nervous system ( CNS ) ( leptomeningeal ) involvement AML may consider treatment Investigator 's discretion follow discussion Medical Monitor , order allow appropriate management . Patient circulate blast count &gt; 50,000/μL ( patient may enrol circulate blast count control hydroxyurea and/or , clinically indicate , leukopheresis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>